Alto Neuroscience Quarterly Cash Flow Statement
NYSE: ANROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
24.37+0.34 (+1.41%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alto Neuroscience free cash flow
In the quarter ended Jun 30, 2026, Alto Neuroscience generated -$19.8 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$19.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Alto Neuroscience cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -27.64M | -26.24M | -16.18M | -14.18M | -17.71M | -15.17M | -15.20M | -16.78M | -16.03M | -13.42M | -11.22M | -9.14M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 200.00K | 184.00K | 157.00K | 200.00K | 100.00K | 171.00K | 170.00K | 200.00K | 100.00K | 97.00K | 112.00K | 100.00K |
| Stock-Based Compensation | 3.55M | 2.82M | 1.95M | 2.19M | 2.00M | 1.97M | 1.57M | 2.00M | 1.89M | 2.18M | 606.00K | 541.00K |
| Change in Working Capital | 2.43M | -2.64M | 359.00K | 1.09M | 832.00K | -1.96M | -312.00K | 1.15M | -127.00K | -661.00K | -331.00K | -723.00K |
| Operating Cash Flow | -19.76M | -27.09M | -11.52M | -9.92M | -13.78M | -16.56M | -13.02M | -11.73M | -11.69M | -10.98M | -11.52M | -7.76M |
| Capital Expenditures | 0 | -556.00K | 0 | 0 | 0 | -24.00K | -506.00K | -1.00M | -340.00K | -224.00K | -352.00K | -43.00K |
| Investing Cash Flow | 0 | -556.00K | 0 | 0 | 0 | -24.00K | -506.00K | -1.00M | -340.00K | -224.00K | -352.00K | -43.00K |
| Debt Issued | — | — | — | — | — | 19.69M | — | — | — | 0 | — | — |
| Debt Repaid | 0 | 0 | 0 | 0 | 0 | -10.21M | 0 | 0 | 0 | 0 | — | — |
| Financing Cash Flow | -273.00K | 114.94M | 50.19M | 153.00K | 613.00K | 9.13M | 49.00K | 1.32M | -234.00K | 134.56M | 43.13M | 49.00K |
| Net Change in Cash | -20.03M | 87.28M | 38.67M | -9.77M | -13.17M | -7.47M | -13.47M | -11.42M | -12.27M | 123.35M | 31.26M | -7.74M |
| Free Cash Flow | -19.76M | -27.65M | -11.52M | -9.92M | -13.78M | -16.58M | -13.53M | -12.73M | -12.03M | -11.21M | -11.88M | -7.81M |
This table shows 12 quarterly periods of Alto Neuroscience's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ANRO's reporting calendar. What is a cash flow statement?